U Bonuccelli

Summary

Affiliation: University of Pisa
Country: Italy

Publications

  1. ncbi request reprint Dopamine agonists in the treatment of Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, 56126 Pisa, Italy
    Expert Rev Neurother 6:81-9. 2006
  2. ncbi request reprint Comparing dopamine agonists in Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Curr Opin Neurol 16:S13-9. 2003
  3. ncbi request reprint The safety of dopamine agonists in the treatment of Parkinson's disease
    Ubaldo Bonuccelli
    University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy
    Expert Opin Drug Saf 7:111-27. 2008
  4. ncbi request reprint Paroxetine in Parkinson's disease: effects on motor and depressive symptoms
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    Neurology 55:1216-8. 2000
  5. ncbi request reprint Pergolide in the treatment of patients with early and advanced Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Clin Neuropharmacol 25:1-10. 2002
  6. ncbi request reprint Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    J Neural Transm 111:1065-73. 2004
  7. ncbi request reprint Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients
    L Petrozzi
    Department of Neuroscience, University of Pisa, Italy
    Neurol Sci 22:83-4. 2001
  8. ncbi request reprint Psychiatric comorbidity in a population of Parkinson's disease patients
    A Nuti
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Eur J Neurol 11:315-20. 2004
  9. ncbi request reprint Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
  10. ncbi request reprint Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia
    R Ceravolo
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    J Neural Transm 113:1787-90. 2006

Detail Information

Publications71

  1. ncbi request reprint Dopamine agonists in the treatment of Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, 56126 Pisa, Italy
    Expert Rev Neurother 6:81-9. 2006
    ..Thus, after a few years of treatment the majority of patients who started on dopamine agonists will be administered levodopa, in a combined dopaminergic therapy, in order to achieve a better control of motor symptoms...
  2. ncbi request reprint Comparing dopamine agonists in Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Curr Opin Neurol 16:S13-9. 2003
    ..Randomized, controlled comparative studies between dopamine agonists are necessary to verify any possible differences in their effectiveness and tolerability in the treatment of Parkinson's disease...
  3. ncbi request reprint The safety of dopamine agonists in the treatment of Parkinson's disease
    Ubaldo Bonuccelli
    University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy
    Expert Opin Drug Saf 7:111-27. 2008
    ..This review focuses on the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease...
  4. ncbi request reprint Paroxetine in Parkinson's disease: effects on motor and depressive symptoms
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    Neurology 55:1216-8. 2000
    ..Depression, as evaluated by Beck Depression Inventory and Hamilton Depression Rating Scale, improved from baseline to final visit (p < 0.05 by analysis of variance)...
  5. ncbi request reprint Pergolide in the treatment of patients with early and advanced Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Clin Neuropharmacol 25:1-10. 2002
    ..The side-effect profile of pergolide is similar to that of other dopamine agonists, and complications such as sleep attack and serosal fibrosis have been rarely reported...
  6. ncbi request reprint Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study
    R Ceravolo
    Department of Neuroscience, University of Pisa, Italy
    J Neural Transm 111:1065-73. 2004
    ....
  7. ncbi request reprint Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients
    L Petrozzi
    Department of Neuroscience, University of Pisa, Italy
    Neurol Sci 22:83-4. 2001
    ..05). The chromosome damage and the increased levels of oxidized purine bases observed in our patients support the hypothesis of oxidative stress as a relevant factor in the pathogenesis of PD...
  8. ncbi request reprint Psychiatric comorbidity in a population of Parkinson's disease patients
    A Nuti
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Eur J Neurol 11:315-20. 2004
    ....
  9. ncbi request reprint Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
    ..This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations...
  10. ncbi request reprint Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia
    R Ceravolo
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    J Neural Transm 113:1787-90. 2006
    ....
  11. ncbi request reprint Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study
    C Rossi
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 17:626-30. 2010
    ..TD patients are characterized by a slower disease progression and a minor cognitive impairment. Striatal density of DAT, as quantified by FP-CIT SPECT, has been reported to correlate with rigidity and akinesia but not with tremor...
  12. ncbi request reprint Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients
    L Petrozzi
    Department of Neuroscience, Clinical Neurology, Movement Disorders Unit, University of Pisa, Via Roma 67, I 56126 Pisa, Italy
    Neurol Sci 23:S97-8. 2002
    ..Different molecular mechanisms underlie cytogenetic alterations observed in peripheral lymphocytes of AD and PD patients...
  13. ncbi request reprint Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer's disease patients
    F Trippi
    Dipartimento di Scienze dell'Uomo e dell'Ambiente, University of Pisa, Pisa, Italy
    Mutagenesis 16:323-7. 2001
    ....
  14. ncbi request reprint IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study
    C Lucetti
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Neurology 60:1995-7. 2003
    ..A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales...
  15. ncbi request reprint Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients
    L Migliore
    Dipartimento di Scienze dell Uomo e dell Ambiente, Pisa, Italy
    Cytogenet Cell Genet 87:41-6. 1999
    ....
  16. ncbi request reprint Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement
    Claudio Lucetti
    Department of Neuroscience, University of Pisa, Italy
    Parkinsonism Relat Disord 12:279-83. 2006
    ..To evaluate in a prospective longitudinal study the evolution of functional disability and the response to dopaminergic therapy in PD patients with and without autonomic involvement...
  17. ncbi request reprint Amantadine in Huntington's disease: open-label video-blinded study
    C Lucetti
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Neurol Sci 23:S83-4. 2002
    ..01). No changes were observed in neuropsychologic and psychiatric assessments after 6 and 12 months of therapy. These data may have relevance to the treatment of HD with amantadine...
  18. ncbi request reprint Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers
    R Ceravolo
    Department of Neurosciences, University of Pisa, Italy
    Neurology 65:1971-3. 2005
    ..They found evidence of preserved presynaptic nigrostriatal function, suggesting that parkinsonism in the X fragile premutation might be related to postsynaptic dopaminergic changes or different neurotransmitter alterations...
  19. doi request reprint 'INDOTEST' in atypical hemicrania continua
    F Baldacci
    Department of Neurosciences, University of Pisa, Pisa, Italy
    Cephalalgia 28:300-1. 2008
    ..In all three cases INDOTEST predicted chronic responsiveness to indomethacin. Thus, in cases of HC with atypical features, INDOTEST could help for a correct diagnosis and therapy...
  20. ncbi request reprint Improvement of motor function in early Parkinson disease by safinamide
    F Stocchi
    Department of Neuroscience and IRCCS Neuromed Pozzilli IS, Disorders Centre, Department of Neuroscience, Universita G D Annunzio, Chieti Pescara, Pescara, Italy
    Neurology 63:746-8. 2004
    ..7-point motor score decrease; p > or = 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses...
  21. ncbi request reprint SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study
    R Ceravolo
    Department of Neuroscience, Clinical Neurology, and Department of Psychiatry, University of Pisa, Italy
    Clin Neuropharmacol 24:221-7. 2001
    ..05 according to an analysis of variance). Our findings suggest that SSRIs do not significantly worsen extrapyramidal symptomatology and may ameliorate depression in patients with PD...
  22. doi request reprint Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction
    R Ceravolo
    Neurology Unit, Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 20:480-5. 2013
    ..However, the potential interference of psychoactive as well as anti-parkinsonian drugs on DAT density should be taken into account...
  23. doi request reprint Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients
    R Ceravolo
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita di Pisa, Pisa, Italy
    Eur J Neurol 18:842-9. 2011
    ..To evaluate the effects of 25-Hz deep brain stimulation of the nucleus tegmenti pedunculopontini (PPTg) on brain metabolic activity...
  24. ncbi request reprint Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging
    M Cosottini
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Acta Neurol Scand 116:37-42. 2007
    ....
  25. ncbi request reprint Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease
    R Ceravolo
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Neurol Sci 24:162-3. 2003
    ..001) occipital hypoperfusion with respect to AD was reported. Our findings confirm that dopaminergic nigrostriatal function is impaired in LBD. The selective occipital hypoperfusion in LBD needs to be further investigated...
  26. ncbi request reprint Dihydroergocryptine in the treatment of Parkinson's disease
    U Bonuccelli
    Institute of Clinical Neurology, University of Pisa, Italy
    J Neural Transm Suppl 45:239-45. 1995
    ..1992; Yoshikawa et al., 1994). In this minireview we resume the data reported about neuroprotective activity and therapeutic efficacy of a new ergot derivative, alpha-dihydroergocryptine (DHEC)...
  27. ncbi request reprint Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients
    C Lucetti
    Department of Neuroscience, University of Pisa, Italy
    Neurol Sci 22:69-70. 2001
    ..The motor cortex reduction of the NAA/Cr ratio in de novo PD patients may reflect an altered neuronal functioning due to a loss of thalamocortical excitatory inputs and may represent an in vivo marker for the diagnosis of PD...
  28. ncbi request reprint Prevalence of headache syndromes in panic disorder
    D Marazziti
    Dipartimento di Psichiatria, University of Pisa, Italy
    Int Clin Psychopharmacol 14:247-51. 1999
    ..This suggests that the comorbidity of headache with panic disorder renders this condition more severe and possibly responsive to different treatments compared to panic disorder alone...
  29. ncbi request reprint A case of sarcoidosis presenting as a non-specific intramedullary lesion
    D Caneparo
    Section of Neurology, Department of Neuroscience, University of Pisa, Pisa, Italy
    Eur J Neurol 14:346-9. 2007
    ....
  30. ncbi request reprint Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients
    L Migliore
    Dipartimento di Scienze dell Uomo e dell Ambiente, Via S Giuseppe 22, 56026 Pisa, Italy
    Int J Hyg Environ Health 204:61-6. 2001
    ..Glutathione S-transferase activity in plasma from PD patients and controls was also measured and the enzymatic activity in PD patients was lower than in healthy controls...
  31. ncbi request reprint New pharmacologic horizons in the treatment of Parkinson disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Italy
    Neurology 67:S30-8. 2006
    ....
  32. ncbi request reprint Orthostatic hypotension in de novo Parkinson disease
    Ubaldo Bonuccelli
    Department of Neuroscience, Section of Neurology, Movement Disorders Unit, University of Pisa, Pisa, Italy
    Arch Neurol 60:1400-4. 2003
    ..It is accepted that orthostatic hypotension is a clinical marker for the diagnosis of multiple system atrophy, but conflicting data indicate that it may also be present in Parkinson disease (PD)...
  33. ncbi request reprint Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    J Neurol 257:S276-83. 2010
    ..Hypomanic and psychotic episodes are best managed with a reduction of DRT performed in hospital also by using atypical antipsychotics low dose...
  34. ncbi request reprint The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease
    Fabio Coppede
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Neurosci Lett 473:248-51. 2010
    ..Moreover, the hOGG1 Ser326Cys polymorphism was not associated with disease age at onset (p=0.791). Overall, present results suggest that the hOGG1 Ser326Cys polymorphism is not associated with sporadic PD...
  35. doi request reprint Role of dopamine receptor agonists in the treatment of early Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:S44-53. 2009
    ....
  36. ncbi request reprint Motor response to apomorphine in patients with Parkinson's disease with long-duration response to levodopa
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Clin Neuropharmacol 25:119-21. 2002
    ..e., postsynaptic versus presynaptic) or transduction pathways are involved in such responses...
  37. ncbi request reprint Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice
    Francesca Vaglini
    Department of Neuroscience, University of Pisa, Via Roma 55, 56125 Pisa, Italy
    Brain Res 973:298-302. 2003
    ..In line with previous data suggesting that dextromethorphan can prevent neuronal damage, our observations supply new evidence regarding the possibility of this compound being of therapeutic use in neurodegenerative diseases...
  38. doi request reprint Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management
    Roberto Ceravolo
    Department of Neurosciences, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:S111-5. 2009
    ..There is no empirical evidence supporting the use of psychiatric drugs for ICDs in PD. Functional neuroimaging studies such as functional MRI and PET can investigate in vivo the neurobiological basis of these pathological behaviours...
  39. ncbi request reprint Role of dopamine agonists in Parkinson's disease: an update
    Ubaldo Bonuccelli
    University of Pisa, Department of Neuroscience, Via Roma 67 56126, Pisa, Italy
    Expert Rev Neurother 7:1391-9. 2007
    ..However, the disease-modifying effect of these agents in Parkinson's disease remains to be ascertained...
  40. ncbi request reprint Myopathic involvement and mitochondrial pathology in kennedy disease and in other motor neuron diseases
    D Orsucci
    Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy
    Curr Mol Med 14:598-602. 2014
    ..It will be important to develop a better understanding of the role of mitochondrial dysfunction in motoneuron diseases, since it may lead to the development of more effective strategies for the treatment of this devastating disorder. ..
  41. doi request reprint Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment
    L Chico
    Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy
    Free Radic Res 47:569-76. 2013
    ..This study, in confirming the occurrence of oxidative stress in AD and MCI patients, shows how it can be related, at least for superoxide dismutase activity in MCI, to APO E4 allele risk factor...
  42. ncbi request reprint Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model
    R Ceravolo
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Acta Neurol Scand 105:32-9. 2002
    ....
  43. pmc Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease
    F Sartucci
    Department of Neuroscience, Clinical Neurology, Pisa University Medical School, Italy
    Neurol Sci 26:395-401. 2006
    ....
  44. pmc Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports
    G Siciliano
    Department of Neurosciences, Neurology Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    J Neurol Neurosurg Psychiatry 71:685-7. 2001
    ....
  45. ncbi request reprint Clinical pharmacokinetics of cabergoline
    Paolo Del Dotto
    Department of Neuroscience, Movement Disorders Unit, University of Pisa, Pisa, Italy
    Clin Pharmacokinet 42:633-45. 2003
    ....
  46. ncbi request reprint Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study
    Claudio Lucetti
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Mov Disord 22:2170-5. 2007
    ..05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex...
  47. ncbi request reprint Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion
    A Chiti
    Division of Neurology, Department of Clinical and Experimental Medicine, University of Pisa IT, Pisa, Italy
    Neurol Sci 34:1871-3. 2013
    ....
  48. ncbi request reprint Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients
    L Migliore
    Department of Human and Environmental Sciences, University of Pisa, Italy
    Neurology 58:1809-15. 2002
    ..Increased lipid peroxidation and oxidative DNA damage have been reported in the CNS. Markers of oxidative stress have been identified in the blood of patients with PD...
  49. ncbi request reprint Electrophysiological evaluation of genito-sphincteric dysfunction in multiple system atrophy
    A Pellegrinetti
    Department of Neuroscience, Section of Neurology, University of Pisa, Pisa, Italy
    Int J Neurosci 113:1353-69. 2003
    ..Even if diagnostic yield is not improved using these investigations they provide evidence of multiple lesion sites other than Onuf's nucleus...
  50. ncbi request reprint Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes
    Lorenzo Kiferle
    Department of Neuroscience, University of Pisa, Via Roma 67, 56127 Pisa, Italy
    Neurosci Lett 422:228-31. 2007
    ..These data might suggest that 5-HTTLPR and 5-HT2A polymorphisms are not major susceptibility factors of psychotic symptoms in PD patients...
  51. ncbi request reprint Molecular implications of the human glutathione transferase A-4 gene (hGSTA4) polymorphisms in neurodegenerative diseases
    Fabio Coppede
    Dipartimento di Scienze dell Uomo e dell Ambiente, University of Pisa, Via S Giuseppe 22, 56126 Pisa, Italy
    Mutat Res 579:107-14. 2005
    ....
  52. ncbi request reprint Clozapine for the treatment of levodopa-induced dyskinesias
    Paolo Del Dotto
    Department of Neuroscience, University of Pisa, Italy
    Lancet Neurol 3:268. 2004
  53. ncbi request reprint "Parkinson-dementia" diseases: a comparison by double tracer SPECT studies
    Carlo Rossi
    Department of Neuroscience, Neurology Section, University of Pisa, Pisa, Italy
    Parkinsonism Relat Disord 15:762-6. 2009
    ..Finally no correlation was found between any regional perfusional changes and nigro-striatal dysfunction. We conclude that neither studies with 123I-FP-CIT nor ECD/SPECT were able to discriminate between DLB and PDD in vivo...
  54. doi request reprint Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study
    Roberto Ceravolo
    Department of Neurosciences, Neurologic Clinic, University of Pisa, Pisa, Italy
    Mov Disord 23:2049-54. 2008
    ..We suggest this disorder to be labeled as "isolated tremor with dopaminergic presynaptic dysfunction"...
  55. ncbi request reprint Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study
    Luciano Gabrielli
    Section of Neurology, Department of Neuroscience, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Int J Psychophysiol 44:83-91. 2002
    ..To this end, a non-task warning paradigm was adopted...
  56. ncbi request reprint Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype
    Michelangelo Mancuso
    Department of Neuroscience, Neurological Clinic, University of Pisa, Via Roma 67, 56126 Pisa, Italy
    Neurosci Lett 444:83-6. 2008
    ..No significant difference was observed between different haplogroups and haplogroup clusters in the cognitive or motor progression of the disease. Our study does not support any association between mtDNA haplogroups and HD...
  57. ncbi request reprint Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats
    Alessandro Napolitano
    Department of Neurosciences, Clinical Neurology, University of Pisa, I 56100, Pisa, Italy
    Parkinsonism Relat Disord 9:145-50. 2003
    ..We conclude that the blockade of central DA catabolism by tolcapone contributes to the greater increase in striatal DA levels achieved with this drug...
  58. ncbi request reprint Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease
    Ferdinando Sartucci
    Department of Neuroscience, Institute of Neurology, University of Pisa, Pisa, Italy
    J Clin Neurophysiol 20:375-81. 2003
    ..The results suggest that the koniocellular subpopulation of RGCs may be particularly vulnerable in early stages of Parkinson's disease...
  59. ncbi request reprint Dopaminergic modulation of visual-spatial working memory in Parkinson's disease
    Alberto Costa
    IRCCS, Fondazione Santa Lucia, Universita di Roma Tor Vergata, Italia
    Dement Geriatr Cogn Disord 15:55-66. 2003
    ..Instead, L-dopa administration had a ameliorative effect on accuracy and reaction times in both visual-spatial and visual-object tasks. These results highlight the role of dopamine in the modulation of the WM function in PD patients...
  60. ncbi request reprint Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  61. ncbi request reprint Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading
    Jose Martin Rabey
    Department of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel
    Clin Neuropharmacol 25:83-8. 2002
    ..In summary, the present results suggest that Short Parkinson's Evaluation Scale is a useful tool in assessing the effect of medication, having the advantage of being easier and quicker...
  62. ncbi request reprint Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients
    Pablo Martinez-Martin
    Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
    Mov Disord 22:1623-9. 2007
    ....
  63. ncbi request reprint Association between amantadine and the onset of dementia in Parkinson's disease
    Rivka Inzelberg
    Department of Neurology, Hillel Yaffe Medical Center, Hadera, Israel
    Mov Disord 21:1375-9. 2006
    ..01). Age of PD onset also significantly influenced the duration of PD until dementia. Amantadine use may delay the onset of dementia in PD patients and may attenuate its severity...
  64. ncbi request reprint Subcutaneous apomorphine for neuroleptic malignant syndrome
    Lorenzo Lattanzi
    Am J Psychiatry 163:1450-1. 2006
  65. ncbi request reprint Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test
    Maria Teresa Pellecchia
    Department of Neurological Sciences, University of Naples Federico II, Naples, Italy
    Ann Neurol 60:611-5. 2006
    ..Our aim was to evaluate the accuracy of the arginine growth hormone (GH) stimulation test in distinguishing between MSA and PD in large populations of patients...
  66. ncbi request reprint The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population
    Michelangelo Mancuso
    Parkinsonism Relat Disord 14:381-2. 2008
  67. ncbi request reprint Activity-based diary for Parkinson's disease
    Johan Marinus
    Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
    Clin Neuropharmacol 25:43-50. 2002
    ....
  68. ncbi request reprint Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
    Ian McKeith
    Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK
    Lancet Neurol 6:305-13. 2007
    ..Diagnostic accuracy, positive and negative predictive values, and inter-reader agreement were the secondary endpoints and a subgroup of possible DLB patients was also included...
  69. ncbi request reprint Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study
    Giovanni Defazio
    Department of Neurology and Psychiatry, University of Bari, Piazza Giulio Cesare 11, I 70124 Bari, Italy
    Arch Neurol 65:1191-4. 2008
    ..To determine whether pain is more frequent among people with Parkinson disease (PD) than among age-matched controls...
  70. ncbi request reprint Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians
    Daniele Ghezzi
    Unit of Molecular Neurogenetics, National Neurological Institute, Carlo Besta, Milan, Italy
    Eur J Hum Genet 13:748-52. 2005
    ..Our study suggests that haplogroup K might confer a lower risk for PD in Italians, corroborating the idea that the mitochondrial oxidative phosphorylation pathway is involved in the susceptibility to idiopathic PD...
  71. ncbi request reprint The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms
    Maria Teresa Pellecchia
    Department of Neurological Sciences, University of Naples Federico II, Naples, Italy
    Mov Disord 23:190-4. 2008
    ..Our results suggest that the impairment of the central mechanisms modulating GH release differs between PSP and MSA-P...